EHC
Encompass Health Corporation
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
120.31
▼ 0.60 (0.50%)
MARKET · —
Price
Open
120.91
Prev close
120.91
Day high
122.30
Day low
120.10
Volume
543.41K
Market cap
$11.87B
P/E (TTM)
20.19
52W range
92.77 – 127.99
Trailing performance
Returnvs SPY
1W
-2.65%
-1.3%
1M
+8.33%
+4.6%
3M
+15.18%
+12.1%
6M
+12.91%
+1.8%
YTD
+13.35%
+1.1%
1Y
-2.61%
-22.6%
3Y
+70.27%
-3.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$11.87B
Enterprise value$15.47B
Revenue (TTM)$6.21B
Gross profit$2.72B
EBITDA$1.46B
Net income$603.70M
EPS (TTM)$5.96
Free cash flow$229.92M
Total cash$107.70M
Total debt$2.84B
Book value / share$26.29
Shares outstanding98.65M
Float97.65M
Short % of float4.18%
Dividend yield0.70%
Beta (5Y)0.60
Valuation & profitability ratios
Trailing P/E20.19
Forward P/E18.02
PEG ratio0.41
Price / sales—
Price / book4.58
EV / revenue2.49
EV / EBITDA10.57
Gross margin43.86%
Operating margin18.05%
Profit margin10.01%
Return on equity24.97%
Return on assets9.80%
Debt / equity82.12
Current ratio1.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $5.94B | $5.37B | $4.80B | $4.35B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $566.20M | $455.70M | $352.00M | $271.00M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $566.20M | $455.70M | $352.00M | $271.00M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.48 | 1.55 | +4.8% |
| Mar 2026 | 1.49 | 1.60 | +7.1% |
| Dec 2025 | 1.30 | 1.46 | +12.1% |
| Sep 2025 | 1.19 | 1.23 | +3.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.36 | 12 | $1.60B | +8.4% |
| Next quarter | 1.60 | 12 | $1.67B | +8.4% |
| Current year | 6.11 | 13 | $6.46B | +8.8% |
| Next year | 6.68 | 13 | $6.99B | +8.3% |
Analyst targets & ownership
Mean target$148.17
High target$155.00
Low target$140.00
Implied upside23.15%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy1 / 12
Hold0
Sell / Strong sell0 / 0
Held by insiders0.87%
Held by institutions100.37%
Institutions holding807
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-194.04K
Net selling
Buy transactions
29
47.19K shares
Sell transactions
6
241.24K shares
Net transactions
+35
Buys less sells
Sell : buy shares
5.1 : 1
Heavily one-sided
Insider-held shares
860.26K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 10, 26 | COLTHARP DOUGLAS EDWARD Chief Financial Officer |
SELL | 18.87K | $2.37M | Direct |
| Aug 10, 26 | TARR MARK J Chief Executive Officer |
SELL | 173.15K | $21.72M | Direct |
| Aug 10, 26 | DARBY JOHN PATRICK General Counsel |
SELL | 8.91K | $1.12M | Direct |
| Jul 16, 26 | REIDY CHRISTOPHER R Director |
STOCK | 340 | $35.86K | Direct |
| Jul 16, 26 | CHRISTIE EDWARD M III Director |
STOCK | 259 | $27.88K | Direct |
| Jul 15, 26 | KATZ LESLYE G Director |
STOCK | 85 | $0 | Direct |
| Jul 15, 26 | WILLIAMS TERRANCE Director |
STOCK | 29 | $0 | Direct |
| Jul 15, 26 | O'CONNOR KEVIN J Director |
STOCK | 19 | $0 | Direct |
| Jul 15, 26 | HAYES CAIN A. Director |
STOCK | 4 | $0 | Direct |
| Jul 15, 26 | CARMICHAEL GREGORY D Director |
STOCK | 29 | $0 | Direct |
| Jul 15, 26 | HERMAN JOAN E Director |
STOCK | 85 | $0 | Direct |
| Jul 15, 26 | SCHLICHTING NANCY M Director |
STOCK | 40 | $0 | Direct |
| May 15, 26 | COLTHARP DOUGLAS EDWARD Chief Financial Officer |
CONVERSION | 27.69K | $912.24K | Direct |
| May 15, 26 | COLTHARP DOUGLAS EDWARD Chief Financial Officer |
SELL | 27.69K | $2.96M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHARBONNEAU ELISSA JOY |
Officer | 22.76K | Stock Award(Grant) |
COLTHARP DOUGLAS EDWARD |
Chief Financial Officer | 241.37K | Sale |
DARBY JOHN PATRICK |
General Counsel | 75.04K | Sale |
FAY EDMUND M |
Officer and Treasurer | 86.33K | Stock Gift |
HERMAN JOAN E |
Director | 49.64K | Stock Award(Grant) |
KATZ LESLYE G |
Director | 49.64K | Stock Award(Grant) |
PRICE ANDREW L. |
Officer | 79.33K | Stock Award(Grant) |
SCHLICHTING NANCY M |
Director | 22.97K | Stock Award(Grant) |
TARR MARK J |
Chief Executive Officer | 267.81K | Sale |
TUER PATRICK WILLIAM |
Chief Operating Officer | 24.75K | Sale |
Moving averages & technicals
SMA 10
123.02
-2.20% from price
SMA 20
118.99
+1.11% from price
SMA 50
111.05
+8.34% from price
SMA 100
107.67
+11.74% from price
SMA 200
106.92
+12.52% from price
EMA 12
120.93
-0.52% from price
EMA 26
117.80
+2.13% from price
EMA 50
113.77
+5.74% from price
RSI (14)
57.9
Neutral
MACD (12,26,9)
3.14
Hist -0.47
ATR (14)
3.54
2.94% of price
Realised vol 30D
38.1%
Annualised
Bollinger upper
130.28
20, 2σ
Bollinger lower
107.69
20, 2σ
50 / 200 cross
Golden
111.05 vs 106.92
Trend bias
Above 200
+12.52%
Risk profile
Beta vs SPY
0.08
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
38.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-26.2%
Peak to trough
Max drawdown 5Y
-33.2%
Peak to trough
ATR 14
3.54
2.94% of price
Beta (reported)
0.60
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
5.92
Put-heavy session
Put / call open interest
0.77
Positioning, not flow
Max pain
125.00
+3.9% from spot
ATM implied vol
42.5%
Nearest strike to spot
Skew (10% OTM)
+5.8%
Puts bid over calls
Call volume
24
Contracts, this expiry
Put volume
142
Contracts, this expiry
Heaviest call OI
140.00
124 contracts
Heaviest put OI
125.00
146 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Here's Why Encompass Health Can Be a Smart Addition to Your Portfolio
Zacks · 22h ago
3 Profitable Stocks We Find Risky
StockStory · 4d ago
What Three Encompass Health Insiders Selling Signals After a Rate Increase
Motley Fool · 6d ago
Encompass Health's CFO Trimmed His Stake as Shares Jumped After Earnings. Here's What to Know
Motley Fool · 6d ago
Should You Worry That Encompass Health's CEO Sold Into a Rally? Here's What to Know
Motley Fool · 6d ago
5 Revealing Analyst Questions From Encompass Health’s Q2 Earnings Call
StockStory · 8d ago
Encompass Health (EHC) Q2 2026 Earnings Call Transcript
Motley Fool · 10d ago
Encompass Health Insider Sold Shares Worth $1,121,711, According to a Recent SEC Filing
MT Newswires · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.